Angiogenesis inhibitors in early development for gastric cancer

Keyphrases

• Gastric Cancer 100%
• Early Development 100%
• Angiogenesis Inhibitors 100%
• Ramucirumab 60%
• Angiogenesis 40%
• Immune Checkpoint Inhibitors 40%
• Expert Opinion 20%
• Clinical Trials 20%
• Therapeutic Potential 20%
• Tumor Growth 20%
• Clinical Setting 20%
• Therapeutic Target 20%
• Area Cover 20%
• Monoclonal Antibody 20%
• Antiangiogenic 20%
• Antiangiogenic Activity 20%
• Tyrosine Kinase Inhibitor 20%
• Second-line Therapy 20%
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 20%
• Nanotechnology 20%
• Vascular Endothelial Growth Factor 20%
• Tumor Progression 20%
• Mammalian Target of Rapamycin Pathway 20%
• Precision Medicine 20%
• New Blood Vessel 20%
• Growth Factor Pathway 20%
• Antiangiogenic Properties 20%
• Immunomodulatory Drugs (IMiDs) 20%
• Molecular Subtype Classification 20%
• Targeted Agents 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Angiogenesis Inhibitor 100%
• Abdominal Cancer 100%
• Ramucirumab 60%
• Antiangiogenic 60%
• Tumor Growth 40%
• Immune Checkpoint Inhibitor 40%
• Clinical Study 20%
• Clinical Trial 20%
• Immunotherapy 20%
• Mammalian Target of Rapamycin 20%
• Vasculotropin 20%
• Protein Tyrosine Kinase Inhibitor 20%
• Monoclonal Antibody 20%